Approval to expand the pediatric indication of flutiform (KRP-108P)
A standalone product development and regulatory theme involving the start of a Phase III clinical trial of KRP-108P for expanding the pediatric indication of flutiform, followed by approval of a partial change to the approved particulars.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.